Janus Henderson Group PLC Lowers Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Janus Henderson Group PLC reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 2.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 153,560 shares of the medical research company's stock after selling 3,993 shares during the quarter. Janus Henderson Group PLC owned 0.08% of IQVIA worth $36,387,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in IQV. Opal Wealth Advisors LLC acquired a new position in shares of IQVIA during the 2nd quarter worth about $27,000. Capital Performance Advisors LLP purchased a new stake in IQVIA in the 3rd quarter valued at about $27,000. Park Place Capital Corp acquired a new position in shares of IQVIA in the 3rd quarter worth approximately $28,000. Itau Unibanco Holding S.A. purchased a new position in shares of IQVIA during the second quarter worth $29,000. Finally, International Assets Investment Management LLC purchased a new position in IQVIA during the 2nd quarter valued at about $32,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Performance

Shares of IQV traded up $2.70 during mid-day trading on Friday, reaching $202.63. 1,388,125 shares of the company's stock were exchanged, compared to its average volume of 2,002,141. The business's fifty day simple moving average is $215.18 and its 200-day simple moving average is $225.11. The stock has a market capitalization of $36.78 billion, a PE ratio of 26.59, a price-to-earnings-growth ratio of 2.09 and a beta of 1.49. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81.

Wall Street Analyst Weigh In

Several brokerages have commented on IQV. JPMorgan Chase & Co. decreased their price target on shares of IQVIA from $279.00 to $240.00 and set an "overweight" rating for the company in a research report on Tuesday, November 5th. Evercore ISI lowered their price target on shares of IQVIA from $270.00 to $265.00 and set an "outperform" rating for the company in a report on Tuesday, October 8th. Robert W. Baird reduced their price objective on shares of IQVIA from $256.00 to $223.00 and set a "neutral" rating on the stock in a report on Friday, November 1st. BTIG Research decreased their price objective on shares of IQVIA from $290.00 to $260.00 and set a "buy" rating for the company in a research report on Friday, November 1st. Finally, StockNews.com lowered IQVIA from a "buy" rating to a "hold" rating in a report on Thursday, November 28th. Five research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $256.50.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.